In a scientific breakthrough, a new medicine has been approved by the United States Foods and Drug administration (FDA) that can treat types of pancreatic cancer, Fox News reported.
Onivyde (irinotecan liposome) is the first medicine in nearly a decade that can treat the aggressive illness that has an average life expectancy of only eight to 11 months.
The drug was approved after a controlled trial was conducted on 770 patients with metastatic pancreatic adenocarcinoma and who had not previously received any chemotherapy.
The patients were injected with the new regimen which includes Onivyde, oxaliplatin, fluorouracil and leucovorin.
According to the results, the patients showed "significant improvements in survival rates and response rates".
Dr Zev Wainberg, professor of medicine and co-director of the UCLA GI Oncology Program in Los Angeles, said, "I am hopeful that this regimen represents a new reference, meaning we will add to this in the future."
However, Dr Marc Siegel, clinical professor of medicine at NYU Langone Medical Center, said that although "the drug is a useful new tool, it is not a game-changer."
Pancreatic cancer is the eighth most common type of cancer in females and tenth most common in males.
Its symptoms include loss of appetite, belly pain, dark coloured urine, jaundice, and weight loss.
This is the fifth poliovirus case from the province in 2024, while one has been reported from Sindh
Diet may not be only good for gut but likely to benefit cognition, motor ability, blood sugar levels
Sunscreen is considered much-needed skin care ritual by many people across globe, however, it may not be essential
"New service to ensure swift medical assistance for critical cases on motorways," says Khawaja Salman Rafique
Chinese researchers propose that gut microbiome is significant aspect to find out people's age
More than 7,400 deaths every day across Europe’s 53 states are caused by tobacco, fossil fuels, UPFs, alcohol